Royce & Associates LP Invests in Protagonist Therapeutics

Summary

Royce & Associates LP has made a new investment of approximately $593,000 in Protagonist Therapeutics, acquiring 12,255 shares during the first quarter. Other institutional investors have also increased their stakes in the company. Protagonist Therapeutics has a market cap of $3.41 billion and reported a quarterly EPS of ($0.19), exceeding estimates. Analysts maintain a positive outlook, with several issuing buy ratings and price targets ranging from $72.00 to $80.00 for the stock.Market Beat

Impact Analysis

This is a company-level event, as it involves an investment by Royce & Associates LP in Protagonist Therapeutics. The investment, alongside other institutional interest, suggests confidence in the company’s future performance, particularly given its recent financial results where the EPS beat estimates. Analysts’ positive outlook and buy ratings, with high price targets, further indicate potential growth opportunities for the stock. Direct impacts include increased market confidence and potential upward pressure on stock prices. Indirect or second-order effects could include heightened interest from retail investors and potential strategic moves by the company to capitalize on this momentum. Investment opportunities include considering buying shares of Protagonist Therapeutics, given the favorable analyst outlook and institutional interest.Market Beat